Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.61 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.46 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.46 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.46 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | RXRB | P28702 | 2/20 | 0.36 |
| ▸ | RXRG | P48443 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28896242 | 0.97 | MGLL (0.59) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL30036309 | 0.97 | MGLL (0.59) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL16164272 | 0.95 | MGLL (0.61) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL10269425 | 0.89 | MGLL (0.52) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL491507 | 0.86 | MGLL (0.53) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL2067336 | 0.86 | MGLL (0.53) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL28906425 | 0.85 | MGLL (0.48) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL23527775 | 0.84 | MGLL (0.52) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL1199146 | 0.84 | MGLL (0.52) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL29956020 | 0.84 | MGLL (0.52) | MGLLTRPV6ORAI1ORAI2ORAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1960 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059984-A | Ester nitrile compound, electrolyte, electrochemical device and vehicle | 北京车和家汽车科技有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122051374-A | Battery monomer, preparation method and application thereof | 浙江晶科储能有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| CN-120081882-A | Method for synthesizing N, N-dimethyl aminoglycoside by catalyzing glycosyl through halogen bond/hydrogen bond | 江西师范大学 | 2025-06-03 | — | — | CN | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| CN-120004822-A | Flexible crystal optical waveguide material and preparation method and application thereof | 湖州师范学院 | 2025-05-16 | — | — | CN | claimed |
| CN-116375787-B | Steroid-derived chiral monoboro Lewis acid catalyst and synthesis method and application thereof | 宁波大学 | 2025-02-28 | — | — | CN | claimed |
| CN-119019883-A | Electrolyte membrane additive, electrolyte membrane and application thereof | 国家电投集团科学技术研究院有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-118666777-A | Design and preparation method of multicellular organ targeting photosensitizer and application of multicellular organ targeting photosensitizer in anti-tumor treatment | 大连理工大学 | 2024-09-20 | — | — | CN | claimed |
| CN-118373743-A | Aromatic diamine containing four trifluoromethyl groups, preparation method and application thereof, polyimide and preparation method and application thereof | 兰州大学 | 2024-07-23 | — | — | CN | claimed |
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | US | claimed |
| EP-1392722-A2 | ECHINOCANDIN PROCESS | Merck & Co., Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| WO-2003105860-A1 | PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | claimed |
| US-6590100-B2 | Reacting an aromatic compound bearing a leaving group and an arylboronic acid and/or its derivatives in the presence of a base and an effective amount of a nickel catalyst | RHODIA CHIMIE (FR) | 2003-07-08 | — | — | US | claimed |
| US-20020173652-A1 | Process for preparing a polyaromatic compound | SHASUN PHARMA SOLUTIONS, INC. | 2002-11-21 | — | — | US | claimed |
| WO-2002083713-A2 | ECHINOCANDIN PROCESS | MERCK & CO., INC. (US) | 2002-10-24 | — | — | WO | claimed |
| US-6051251-A | Liposome loading method using a boronic acid compound | ALZA CORPORATION (US) | 2000-04-18 | — | — | US | claimed |
| EP-0952842-A2 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-11-03 | — | — | EP | claimed |
| WO-1997038664-A2 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | claimed |
| WO-1995005081-A1 | BIOCIDAL COMPOSITIONS CONTAINING ORGANOBORON COMPOUNDS | U.S. BORAX INC. (US) | 1995-02-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | LIPE, CEL, LIPA | MGLL 16/4885TRPV6 4106/4885ORAI1 4207/4885 |
| US-20020173652-A1 | Process for preparing a polyaromatic compound | PAH, ALK, ITPA | MGLL 3922/4885TRPV6 380/4885ORAI1 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.